Browse the evidence

JMV-449 augmented the insulinotropic actions of both GIP and GLP-1.

Combining JMV-449 with incretin therapies may improve insulin response in patients.

JMV-449 inhibited food intake in overnight fasted lean mice.

JMV-449 may be useful in appetite regulation strategies for weight management.

Novel pharmacological and surgical treatment strategies for obesity and hypertension can play a role in the prevention and treatment of heart failure.

Practitioners should integrate treatment strategies for obesity and hypertension to improve heart failure outcomes.

GLP-1 RA users had a higher incidence of delayed wound healing (18.5% versus 7.5%) compared to nonusers.

Practitioners should monitor GLP-1 RA users for delayed wound healing post-surgery.

GLP-1 RA users had lower seroma rates (4.9% versus 14.0%) compared to nonusers.

Practitioners may consider GLP-1 RAs for potentially reducing seroma formation post-surgery.

GLP-1 RA users had higher rates of type 2 diabetes (55.6% versus 29.5%) compared to nonusers.

Understanding the diabetes status of patients may inform perioperative management strategies.

Obesity is a global epidemic and a chronic, progressive disease.

Recognizing obesity as a chronic disease can influence treatment approaches.

The study aims to understand the use of semaglutide for treating obesity and its pharmacological mechanism.

The study may provide insights into how semaglutide works, aiding in treatment decisions.

Metabolic benefits of bariatric surgery may fatigue over time.

Clinicians should monitor patients post-surgery for diminishing metabolic benefits.

Over half of patients with type 2 diabetes fail to meet glycemic targets due to clinical inertia.

Practitioners should be aware of the impact of clinical inertia on treatment outcomes.

Microneedle (MN)-based technologies provide a painless drug delivery approach that targets adipose tissue directly, minimizing systemic exposure and reducing the required dosage.

Practitioners may consider MNs as a viable alternative for delivering anti-obesity medications effectively.

The use of nano-based medications through transdermal delivery is important for effective obesity treatment.

Practitioners should consider incorporating nano-based medications for better treatment outcomes.

Tirzepatide's effect is largely mediated by its GIP component.

Understanding that GIP mediates tirzepatide's effects can help practitioners optimize treatment strategies.

Tirzepatide has a half-life of five days, allowing for once-weekly administration.

Practitioners can schedule tirzepatide administration once a week due to its five-day half-life.

Powerlifters exhibited significantly less shoulder extension and horizontal abduction, and hip flexion, extension, and adduction than recreationally strength-trained men.

Powerlifters may need to address limitations in shoulder and hip ROM to optimize performance.

No statistically significant differences in resting blood variables or body composition were observed between the AEL and TRAD protocols after 4 weeks of training.

Practitioners may not expect significant changes in hormonal responses or body composition from AEL compared to traditional training.

Results marginally favored the use of AEL, but did not support significant improvements in body composition or hormonal responses.

AEL may have slight advantages, but practitioners should not expect major changes in outcomes.

Canagliflozin has shown benefits in reducing progression of renal disease and heart failure in patients with type 2 diabetes.

Canagliflozin may be a beneficial treatment option for managing renal and heart health in diabetic patients.

The combination of canagliflozin and metformin in a single tablet may improve medication adherence in type 2 diabetes.

Using a fixed-dose combination may enhance patient compliance with diabetes treatment regimens.

The goal of management in T2D patients with significant fibrosis is to slow the progression of liver disease and reduce associated clinical events.

Clinicians should aim to adapt therapies to manage liver disease progression in diabetic patients.

Bariatric surgery can enforce prolonged remission of Type 2 diabetes mellitus (DM2) in a proportion of patients.

Bariatric surgery may be considered as a treatment option for patients with DM2 seeking remission.

The gut releases several hormones upon feeding that affect satiety and metabolism.

Understanding gut hormone release can inform dietary strategies for managing satiety and metabolism.

The amount of excess weight reduction after bariatric surgery varies by procedure, with laparoscopic adjustable gastric banding reducing excess weight by 49% and Roux-en-Y gastric bypass by 76%.

Practitioners should inform patients about expected weight loss outcomes based on the type of surgery.

Coconut oil and kernel flakes failed to induce favorable lipid changes comparable to coconut milk supplementation.

Coconut oil and kernel flakes may not be effective for improving lipid profiles compared to coconut milk.